Podcasts about clinical trials

because the patient had two other conditions, or was seventy-eight, or was pregnant, and got excluded from the trial. Then they showed up anyway, and somebody had to decide.Brigham Hyde co-founded Atropos Health out of research that began at Stanford, where a doctor could ask what the data said about the patient in front of them and get an answer back in a day or two. This year that work moved into the EHR workflow itself. We get into what that takes. What a health system needs in place before go-live, who reviews the evidence before a clinician sees it, which specialties adopted first, and how the conversation with CMIOs has changed in three years.Know which clinical questions your literature tools answer, and which they never will.Understand what evidence in the EHR workflow needs from informatics before go-live.Learn how clinician review fits in without adding steps to the visit.Hear how CMIOs are evaluating this category right now.Brigham Hyde, PhD, CEO and Co-Founder, Atropos HealthMegan Antonelli, Chief Executive Officer, HealthIMPACT Live Subscribe to Digital Health Talks on Apple Podcasts, Spotify, YouTube, or wherever you listen.Learn more about HealthIMPACT Live events, virtual forums, and healthcare leader conversations at healthimpactlive.com.Interested in being a guest, sponsoring, or joining the HealthIMPACT community? Visit healthimpactlive.com/digital-health-talks.

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInHumanity Rx PodcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What does a urologist actually need to know to confidently manage advanced prostate cancer in the clinic? On this episode of BackTable Urology, host Dr. Ruchika Talwar interviews Dr. Kristen Scarpato, director of the advanced prostate cancer clinic at Vanderbilt University Medical Center, and Dr. Jason Hafron, chief medical officer of the Michigan Institute of Urology. They break down how the landscape has shifted, why more patients stay in urology for treatment, and how to select and monitor therapy based on disease state, comorbidities, and patient goals. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Bayer https://www.bayer.com --- Timestamps 00:00 - Introduction02:41 - Shift to Urology-Led Advanced Prostate Management07:07 - Sorting Therapies by Disease State10:33 - Treatment Intensification and Doublet Therapy17:54 - ARPI Selection and the Four Ps Framework25:46 - Managing Financial Toxicity29:30 - Monitoring, Labs, and Imaging34:11 - Red Flags and Comanagement36:49 - When to Refer to Medical Oncology41:11 - Future Directions and Practice Economics46:33 - Closing Remarks --- More about this episode The discussion covers sorting therapies by disease state rather than drug class, doublet and triplet intensification, the nuances of choosing between abiraterone, enzalutamide, apalutamide, and darolutamide, and Dr. Hafron's “four Ps” framework for drug selection. Dr. Scarpato addresses financial toxicity, surveillance protocols, and red flag symptoms. Both guests share their referral triggers for medical oncology, approaches for oligometastatic disease and metastasis-directed therapy, and practical tips for running an advanced prostate cancer clinic. --- Resources Advanced Prostate Cancer: AUA/SUO Guidelinehttps://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 (JCO)https://ascopubs.org/doi/10.1200/JCO-25-02834 ARACOG (AFT-47): Darolutamide vs Enzalutamide and Cognitive Function, ClinicalTrials.gov NCT04335682https://clinicaltrials.gov/study/NCT04335682 ARASENS: Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer (NEJM)https://www.nejm.org/doi/full/10.1056/NEJMoa2119115 PSMAddition: 177Lu-PSMA-617 Plus Standard of Care in mHSPC, ClinicalTrials.gov NCT04720157https://clinicaltrials.gov/study/NCT04720157 Medicare Plan Finder, referenced on air for comparing Part D out-of-pocket drug costshttps://www.medicare.gov/plan-compare/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

There is an urgent need for safe and effective therapies to improve outcomes for patients with relapsed osteosarcoma. Viscum album extract (Iscador P, Iscador AG, Arlesheim, Switzerland) is a mistletoe extract manufactured from the leaves, stems and berries of Viscum album L., grown on pine trees (P = Pini). It has shown efficacy and safety in lab experiments and small clinical trials for patients with relapsed osteosarcoma. Data from a small pilot study in Italy paved the way for developing a larger clinical trial in the United States to test the use of Viscum album extract for children, teenagers, and young adults with osteosarcoma that has come back and can be removed with surgery. Another goal of this study is to learn more about what impact Viscum Album extract may have on patients' quality of life, tumor biology and immune system during treatment.

Luister naar de De VVE Podcast. Een initiatief van de Nederlandse Vereniging voor epidemiologie. Hierin voeren Dr. Bart Torensma, Dr. Marissa van Maaren en Dr. Sander van Kuijk tal van gesprekken met aansprekende wetenschappers over boeiende thema's in de wonderlijke wereld van de epidemiologie. Bedoeld als intellectuele verdieping en stapsteen in de VVE-ambitie om de epidemiologische gemeenschap verder met elkaar te verbinden. In deze aflevering #11: Prof. dr. Kit C.B. Roes: Professor of Biostatistics, Radboud University Medical Center: IQ Health Wie bewaakt een klinische trial terwijl die nog loopt? Dat is het werk van de Data Safety Monitoring Board: een onafhankelijke commissie die tussentijds meekijkt naar veiligheid, effect en datakwaliteit, en adviseert of de studie door kan, aangepast moet worden of moet stoppen.Klinkt overzichtelijk, maar de praktijk is dat zelden. Wat als de data iets laten zien waar niemand op rekende? Hoe communiceer je met een sponsor zonder die te ontblinden? En wanneer wint klinisch oordeel het van een statistische stopregel?In deze aflevering duiken we in de wereld van DSMB's: hoe ze werken, waar het misgaat en wat je vooraf moet regelen om ze hun werk goed te laten doen.Boek: Data Monitoring Committees in Clinical Trials: A Practical PerspectiveAuthor(s):Susan S. Ellenberg, Thomas R. Fleming, David L. DeMets. Print ISBN:9781119512653 |Online ISBN:9781119512684 |DOI:10.1002/9781119512684Artikelen:1. DeMets DL, Ellenberg SS. Data Monitoring Committees — Expect the Unexpected. N Engl J Med.2016;375(14):1365-1371. DOI: 10.1056/NEJMra1510066Auteurs: David L. DeMets (Department of Biostatistics and Medical Informatics, University of Wisconsin–Madison) en Susan S. Ellenberg (Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine). Onderdeel van de NEJM-serie "The Changing Face of Clinical Trials". Gepubliceerd 6 oktober 2016.2. Cartwright MJ, Friede T, Lawrence D, May E, Mütze T, Roes K. Stakeholders' Perspectives on Current Issues in Data Monitoring Committees. Biometrical Journal. 2024;66(7):e202300384. DOI: 10.1002/bimj.202300384Auteurs: Michael J. Cartwright (Parexel International, Sheffield, UK), Tim Friede (University Medical Center Göttingen / DZHK), David Lawrence en Tobias Mütze (Novartis Pharma AG, Basel), Emma May (ICON PLC / BioNTech SE), Kit Roes (Radboudumc, Nijmegen). Open access (Creative Commons).3. DAMOCLES Study Group. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365(9460):711-722. DOI: 10.1016/S0140-6736(05)17965-3Corresponderend auteur: Prof. Marion K. Campbell (Health Services Research Unit, University of Aberdeen). Groepsleden: A.M. Grant, D.G. Altman, A.G. Babiker, M.K. Campbell, F. Clemens, J.H. Darbyshire, D.R. Elbourne, S.K. McLeer, M.K.B. Parmar, S.J. Pocock, D.J. Spiegelhalter, M.R. Sydes, A.E. Walker, S.A. Wallace. Gefinancierd door het UK NHS Health Technology Assessment Programme. Gepubliceerd 19 februari 2005.

Saturday, September 26, 2026 — Week 39   CAMP4 ASCEND — WEBINAR #131 - SYNGAP1 ASCEND Phase 1/2 Trial: What You Need To Know. - Monday, Sept. 28 — 12 PM PT / 3 PM ET / 19:00 UTC. - Families: come hear directly from CAMP4 + ask your questions. https://cureSYNGAP1.org/AscendCT   ARGENTINA — PATH TO THE CLINICAL TRIAL - CAMP4 + LATAM hybrid meeting: “Path to the Clinical Trial in Argentina.” - Remember how they got here: THE CONFERENCE. Community → relationships → trial readiness. - Recording: https://youtu.be/UuhOIzSEKH4   SYNGAP1 LEADERS REPRESENTING OUR COMMUNITY - Incoming Board Chair Eric Moulton at Newborn Screening Bootcamp in DC. Critical that SYNGAP1 is involved in NBS — find patients sooner. Thank you RARE Foundation. https://www.rareadvocates.org/newborn-screening-bootcamp/ - Vicky Arteaga + Allison Hirsch represented CURE SYNGAP1 at Rare Diseases International at the UN. https://www.linkedin.com/posts/rare-diseases-international_unga81-rarediseases-globalhealth-activity-7508918814357610496-xtZS   WARRIORS - Wednesday Warrior #237: Matteo in NYC — happy 1st birthday! https://cureSYNGAP1.org/Warrior   TAKE RESPIRATORY SERIOUSLY — JAXON IN ICU - Aaron Harding documented Jaxon's ICU experience day-by-day. A difficult family experience worth reading directly. Add serrapeptase to your regime.  - Aaron's posts: https://www.facebook.com/aaron.j.harding.5 - Willsey paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC11885846/ Another paper is coming soon.   COMMUNITY IN ACTION - LATAM: One Voice for SYNGAP1 — VOCES! https://cureSYNGAP1.org/Voces - Auburn Delta Sigma Phi + Wyatt Jones: Delta Sig for SYNGAP1. https://cureSYNGAP1.org/auburn26   CURE SYNGAP1 CONFERENCE — DENVER - Dec. 3–4. Science Day: 156 registered. Family Day: 137, including 27 kids/Syngapians. - REGISTRATION ENDS OCT. 31. Hotel rooms going fast — register + book now. https://cureSYNGAP1.org/Reg26   PUBMED + SCIENCE - PubMed 2026: 54. +15 vs Week 39. Last year finished at 61, +9 vs the year. https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date - NEW: Pekka Postila team — years of CURE SYNGAP1 support + partnership studying missense mutations. - Molecular modeling supports canonical RasGAP + Plexin-like RapGAP mechanisms; missense variants can disrupt protein stability AND catalysis; other insights. - Paper: https://doi.org/10.1016/j.yjsbx.2026.100162   USA: Use ICD-10 code F78.A1.   SOCIAL MATTERS 5,288 LinkedIn. https://www.linkedin.com/company/cureSYNGAP1/ 1.62K YouTube. https://www.youtube.com/@CureSYNGAP1 11.1K X. https://twitter.com/cureSYNGAP1 43.7K Instagram. https://www.instagram.com/cureSYNGAP1/   Like + subscribe wherever you listen. https://cureSYNGAP1.org/podcasts/syngap10/ Episode 221 of #Syngap10 #SYNGAP1 #CureSYNGAP1 #Podcast #PatientAdvocacy

In this Episode:Clinical research often excludes the diversity of everyday life, making real-world access to psychedelic therapy look very different than a trial setting. As Dr. Alan Davis highlights, thorough preparation and a safe, trusting therapeutic relationship are essential to preventing harm and fostering genuine healing.Key Takeaways:The Human Connection to Healing: Clinical trials often try to isolate a drug's biological effect, but decades of psychotherapy research show that therapeutic alliance and thorough preparation are the primary drivers of positive outcomes.Clinical Trials Exclude Real-World Realities: Rigid screening criteria in research leave out the complex, diverse realities of everyday people, highlighting a need for naturalistic and community-based settings to understand how psychedelics work in practice.Internal Protection Isn't Brokenness: Trauma-response mechanisms like dissociation or hypervigilance are protective strategies built for survival; healing requires a slow, gentle approach rather than trying to “demolish” one's defensive structures overnight.Chapters:00:00:00 - Intro00:08:00 - Alan's Story00:18:19 - Clinical Trials00:36:18 - Dosages00:41:39 - Addiction, Safety, Healing00:51:25 - Treatment and Diversity00:58:15 - Gurus and the System01:10:07 - The Harm of Doing Good01:25:57 - Psychedelic Hopes and DreamsMore From Our Guest:Follow Dr. Alan K. Davis on LinkedInThe Center for Psychology Drug Research and Education at the Ohio State UniversityRead the companion article on our blog.This podcast is edited by Chad Eschman. Our music is by Mic Coats. Psychedelic Passage is your partner in safe, supported, and effective psychedelic journeys. As the first concierge service in the U.S., we connect you with vetted facilitators who value integrity and expertise.Start your free Match Making Process, join our Online Learning Community, and explore a range of educational articles at psychedelicpassage.com.

Send us Fan MailWhat can hundreds of thousands of Reddit posts tell us about the side effects of GLP-1 medications?In this episode of Causes or Cures, I talk with researcher Neil K. R. Sehgal about his recent study examining self-reported side effects of semaglutide and tirzepatide, commonly known by brand names including Ozempic, Wegovy, Mounjaro, and Zepbound.Neil and his colleagues used AI to analyze more than 410,000 Reddit posts mentioning the medications. Among users who reported taking them, researchers found plenty of familiar side effects, particularly gastrointestinal symptoms, but they also identified potential signals involving fatigue, menstrual changes, and temperature-related symptoms such as chills and hot flashes. We talk about why clinical trials can't capture every possible side effect before a drug reaches the broader population, how AI can sift through enormous amounts of online conversation, and why finding a signal on Reddit is not the same thing as proving that a medication caused it.We also get into a bigger question: Could social media eventually become a useful early-warning system for drug safety?In this episode, we discuss: why Neil turned to Reddit to study GLP-1 experiences; how AI analyzed more than 400,000 posts; which potential side-effect signals emerged; the difference between correlation, a safety signal, and causation; how researchers distinguish genuine signals from social-media influence; and how AI and online communities could complement traditional pharmacovigilance.About Neil: Neil K. R. Sehgal is a researcher affiliated with the University of Pennsylvania's Department of Computer and Information Science and Leonard Davis Institute of Health Economics. His research includes using large-scale digital data to better understand patient experiences and healthcare. He led the analysis and was first author of the study discussed in this episode. Read the study: Self-reported side effects of semaglutide and tirzepatide in online communities — Nature HealthWork with Eeks? Perhaps you are a good match. Keep Causes or Cures Ad-Free with Listener SupportYou can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow on X. Or Facebook here.On Youtube.Or TikTok.SUBSCRIBE to the Eeks Weekly here! (the bits not posted on socia media)Support the show

In this episode of The Lead, host Cinzia Monaco, MD, PhD, is joined by Kinan Kneizeh, MD,  and Konstantinos Vlachos, MD, PhD, to discuss "Pulsed Field Ablation Versus Sham to Treat Atrial Fibrillation: The PFA-SHAM Randomized Clinical Trial." The panel examines the trial's sham-controlled evidence for the effects of pulsed field ablation on atrial fibrillation recurrence, quality of life, AF burden, and psychological well-being, while considering placebo effects, study limitations, and the applicability of the findings to clinical practice. Learning Objectives:  1. Describe the design, patient population, endpoints, and key findings of the PFA-SHAM randomized clinical trial. 2. Evaluate the effects of pulsed field ablation compared with a sham procedure on atrial fibrillation recurrence, AF burden, quality of life, and psychological well-being. 3. Assess the trial's limitations, potential placebo effects, and applicability to the management of patients with symptomatic atrial fibrillation. Host: Cinzia Monaco, MD, PhD Guests: Kinan Kneizeh, MD and Konstantinos Vlachos, MD, PhD Disclosures: C. Monaco  • No relevant disclosures K. Kneizeh  • No relevant disclosures K. Vlachos, MD, PhD  • No relevant disclosures  

Plus: AI biotech firm Enveda doubles valuation to $2 billion. And Finnish drone maker Sensofusion seeks $344 million in Helsinki IPO. Danny Lewis hosts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A panel with representatives from biotechnology companies Sepul Bio, Alkeus and AAVantgarde.

Fitz Koehler is a fitness expert, race announcer, author, and breast cancer survivor whose career spans decades of helping people move, train, and live healthier lives. After earning a master's degree in exercise and sport sciences, she built the Fitzness brand, launched the Morning Mile school fitness program, and became one of the country's most recognizable voices at endurance events before cancer abruptly shifted the conversation. She spent 15 months enduring chemotherapy, surgery, and radiation after discovering breast cancer shortly after receiving a clean mammogram. She kept traveling, announcing races, and working through treatment while watching the body she had spent a lifetime building become weaker by the week. Instead of asking why cancer happened, she focused on the only things she believed remained under her control: movement, nutrition, sleep, and mental health. The conversation explores where personal agency ends and biology takes over. Koehler argues that exercise is not about chasing perfection or preventing every diagnosis. It is about building physical reserve before illness arrives and preserving strength, mobility, and independence during treatment. She rejects wellness snake oil, fad supplements, and miracle cures in favor of practical habits rooted in exercise science and lived experience. The discussion also confronts a harder truth. Koehler did everything “right” and still developed cancer. That tension becomes the center of the episode. Fitness cannot eliminate randomness, but it can influence how people experience treatment, recover from surgery, and reclaim their lives afterward. The conversation moves beyond motivation and into survivorship, exercise oncology, cancer rehabilitation, evidence-based nutrition, and the limits of individual control inside a healthcare system that often tells patients what they should do without showing them how to do it. Along the way, the conversation wanders through kickboxing, Cinnabon, Jean-Claude Van Damme, chocolate-covered Cheetos, Jerry Seinfeld playing during chemotherapy stretches, and why the simplest advice is often the hardest to follow. Beneath the humor sits a larger argument: preparing the body for hardship is not about living forever. It is about living better when life inevitably gets difficult. RELATED LINKSFitz Koehler⁠Fitzness⁠The Morning Mile⁠You. Supercharged!⁠My Noisy Cancer Comeback⁠Your Healthy Cancer Comeback⁠UF Health Cancer Center⁠American College of Sports Medicine Exercise Is Medicine⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

2026-09-11 Hosts Craig Lipset and Jane Myles were joined by Becky Kottschade and Dr. Tufia Haddad from the Mayo Clinic to share the evolution of Clinical Trials Beyond Walls, Mayo Clinic's program for bringing digital and decentralized capabilities into clinical research.Building on Mayo's experience with remote patient monitoring, the team started by centralizing capabilities, establishing best practices, and testing new approaches in investigator-initiated trials before scaling more broadly. They discuss the importance of giving participants options for how and where they engage in a trial, what they've learned about reaching patients beyond traditional geographic boundaries, and the unexpected growth in participation from rural communities.The conversation also explores how Mayo is making these capabilities part of its standard trial approach, the challenge of measuring decentralization across studies, and what comes next—including expanding opportunities to involve local healthcare providers in research.Read their recent publication here -- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2849940Follow the Decentralized Trials & Research Alliance (DTRA) on LinkedIn and X. Learn more about Membership options and our work at www.dtra.org.

"If you want something bad, you have to fight for it. Step up you game, Scott. Break out the L-word". Today we discuss a little more on the Epicrispr clinical trial and preview the upcoming Scholar Rock, Soufflé and Dyne phase I/II clinical trials. As you know, the Devil is in the details. We are tingling with anticipation for the upcoming clinical trial report from Epicrispr to be presented at the World Muscle Society first week of October (DNA methylation and DUX4 target gene expression data from biopsies, please). We are still very hopeful for the Avidity Phase 3 trial currently in 45 sites around the world! Sure the DM1 trial tanked, but their DMD trial is progressing well. Regardless, new therapeutic approaches are here. We are very high on Soufflé's cell specific targeting platform as well as Dyne's alternate transferrin receptor targeting, both of which we hope will allow for increased dosing, more DUX4 knockdown, and greater intervals between dosing. We are also cautiously optimistic about Scholar Rock entering the FSHD space coming off of their recent FDA approval for a combined therapy in SMA. Truly exciting times (and more to come!), and we will try to keep you all updated on the science.

Send us Fan MailThis week on The Incubator Podcast, Ben and Daphna dig into four studies reshaping bedside decisions. They open questioning whether routine DAT screening for ABO and RhD incompatibility still earns its place, finding transcutaneous bilirubin alone predicts phototherapy need just as well. Next, a Swedish national registry of over two million births links missed intramuscular vitamin K, and rising oral substitution, to a near-doubling of bleeding and intracranial hemorrhage risk. Ben then presents the PHILODENDRON pilot trial out of Milan, testing initial delivery-room CPAP of 5 versus 8 cmH2O in infants under 30 weeks, feasible and safe, but not yet enough to settle the physiology question. Daphna closes Journal Club with a SART-linked study tying IVF conception to significantly higher odds of VACTERL association. The week wraps with Ben and Eli on Neo News, unpacking a study showing birth certificates miss nearly 40% of true NICU admissions, with troubling racial disparities.----Utility of DAT in Low-Risk Neonates With ABO or RhD Incompatibility. Tsai TL, Ma T, Nester T.Pediatrics. 2026 Sep 1;158(3):e2026076989. doi: 10.1542/peds.2026-076989.PMID: 42642037Vitamin K Prophylaxis in Newborns and Bleeding in Infancy. Simatou E, Tsamantioti E, Hallström A, Stephansson O, Razaz N, Persson M, Bolk J.JAMA Pediatr. 2026 Sep 1;180(9):995-1004. doi: 10.1001/jamapediatrics.2026.2606.PMID: 42440325Initial CPAP of 5 versus 8 cmH2O during delivery room stabilisation of very preterm infants: the PHILODENDROOM pilot randomised trial. Cavigioli F, Bresesti I, Castoldi F, Gatto S, Lupo E, Rossi S, La Verde A, Bianchi S, Meneghin F, Viaroli F, Pivetti V, Manfredini V, Cannata G, Bastrenta P, Fontana P, Stucchi I, Daniele I, Chiera M, Lista G.Eur J Pediatr. 2026 Aug 17;185(9):673. doi: 10.1007/s00431-026-07322-6.PMID: 42608615 Free PMC article. Clinical Trial.In Vitro Fertilization and VACTERL Birth Defects. Tark JY, Richard MA, Schraw JM, Fisher SC, Betancourt D, Stone SL, Forestieri NE, Baker VL, Cameron K, Eisenberg ML, Belva F, Lu Y, Williams CL, Sutcliffe AG, Lupo PJ, Luke B.JAMA Netw Open. 2026 Aug 3;9(8):e2629355. doi: 10.1001/jamanetworkopen.2026.29355.PMID: 42616500 Free PMC article.Birth certificate data substantially misrepresent actual NICU admissions, including among most vulnerable. Hughes CS, Lorch SA, Schmitt S, Passarella M, Phibbs CS.J Perinatol. 2026 Jul;46(7):1307-1312. doi: 10.1038/s41372-026-02726-6. Epub 2026 May 27.PMID: 42204354Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Mike Fong loves poker and playing the odds. Doctors gave him a 60% chance of surviving lymphoma that returned after four years cancer-free. Still, Mike is hopeful after joining a new CAR T clinical trial called "Triple Threat" that targets three of the most common cancer mutations.

Mike Fong loves poker and playing the odds. Doctors gave him a 60% chance of surviving lymphoma that returned after four years cancer-free. Still, Mike is hopeful after joining a new CAR T clinical trial called "Triple Threat" that targets three of the most common cancer mutations.

Professor Howard Gluckman speaks to Amy MacIver about an experimental drug being developed to regenerate human teeth. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Send us Fan MailBen and Daphna dig into a pilot RCT that asks a deceptively simple delivery-room question: should very preterm infants start on CPAP of 5 or CPAP of 8 cmH2O? The PHILODENDRON trial, out of Milan's Buzzi Children's Hospital, randomized 56 babies born between 26 and 29 weeks to find out — testing feasibility, safety, and early physiological adaptation before committing to a larger multicenter trial. No major safety signals emerged, but babies on lower CPAP reached surfactant thresholds faster, while higher CPAP trended toward fewer air leaks and shorter ventilation. Ben and Daphna weigh the physiology against the data, and ask whether trials like this even test the right question in the first place.----Initial CPAP of 5 versus 8 cmH2O during delivery room stabilisation of very preterm infants: the PHILODENDROOM pilot randomised trial. Cavigioli F, Bresesti I, Castoldi F, Gatto S, Lupo E, Rossi S, La Verde A, Bianchi S, Meneghin F, Viaroli F, Pivetti V, Manfredini V, Cannata G, Bastrenta P, Fontana P, Stucchi I, Daniele I, Chiera M, Lista G.Eur J Pediatr. 2026 Aug 17;185(9):673. doi: 10.1007/s00431-026-07322-6.PMID: 42608615 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

In the fourth episode of Season 5 on the Neuroethics of Psychedelics, we speak with Dr. Edward Jacobs about post-trial access to psychedelics among certain patients.Dr. Jacobs is currently a postdoctoral research fellow at Johns Hopkins' Center for Psychedelic and Consciousness Research and the Associate Director of HOPE – The Hub at Oxford for Psychedelic Ethics. He is also a contributing writer to ‘The Ethics Corner' at The Psychedelic Practitioner.In this episode, Dr. Jacobs discusses the challenges that can arise when participants who benefit from psychedelic treatments during clinical trials lose access to them once a study ends. Drawing on his work on post-trial access to psychedelics, he explores the ethical case for continued access, as well as the clinical, regulatory, and institutional infrastructure that would be needed to provide it safely and responsibly.Episode contributors:Host: Dr. Lavinia UscatescuAudio editor: Sarah Schultz

Clinical development organizations are facing mounting pressure to do more with increasingly complex protocols, larger data sets and tighter timelines. While automation has improved individual processes, many of the industry's most persistent delays continue to occur between tasks, systems and teams. In this sponsored episode of The Top Line, host Lauren Ledger sits down with Greg Lever, director of AI and Technology Solutions at IQVIA, to discuss why agentic AI is gaining attention across clinical operations. Lever explains how the conversation is shifting from task automation to workflow orchestration, with AI systems designed to coordinate activities, connect information and help reduce operational bottlenecks. The episode explores where sponsors can find the greatest opportunities for improvement, what it takes to move from pilots to enterprise-scale adoption, and how clinical roles may evolve as routine work becomes increasingly automated. The discussion also addresses the importance of data connectivity, governance and organizational readiness in building trusted AI programs. Listen now for a forward-looking conversation about how people, processes and intelligent systems could redefine the future of clinical trial execution.See omnystudio.com/listener for privacy information.

In recent weeks the results (announced by press release) of 2 major placebo-controlled randomized trials—ZEUS, testing an interleukin-6 (IL-6) blocker vs inflammation, and HORIZON, testing a drug to lower Lp(a), indicated failure to achieve their primary endpoint.Are we maxxed out for new treatments vs heart disease, as this article in the WSJ (←gift link) today asserts? “Cardiovascular drug development is starting to look a bit like the modern oil industry. The easy wells have been tapped. What's left is in deep water: expensive, technically perilous and less likely to strike oil.”Or is it more complicated? Are the trial results and reasons for failure different?I wrote a recent Ground Truths —The Coronary Artery Inflammation Controversy— on the data (what has been released to date) and my take. But I wanted to vet this with another physician-scientist who is studying atherosclerosis and turned to Prof Marios Georgakis, from the University of Munich, who as I mentioned in the previous piece, wrote a brilliant analysis of ZEUS and is also doing writing about HORIZON.Many years ago we went through a “CV winter” when the biopharma companies largely shunned doing clinical trials for heart disease. They thought the field had been maxxed out. After a lapse of several years, there have many trials undertaken with positive results and substantial progress for better treatments vs heart disease. Both Marios and I remain optimistic that we are a long way from maxing out, as you'll learn from the podcast. Heart disease is the number one global killer, for both men and women. That's despite all the progress that has been made to date.Thanks for your support of Ground Truths and to Dr. Julie Kellogg, Vau Geha, Ralph Horwitz, Jessica Coffman, Michael G. Levin, MD, and mopre than 400 others for tuning into my live video with Marios Georgakis! **********************************Ground Truths has 215,000 subscribers from every US state and 214 countries. There are over 310,000 followers of Ground Truths so nearly 100,000 folks who can easily convert to be free subscribers. Please consider doing that…it's free.Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you're not a subscriber, please join!If you found this interesting PLEASE share it!The proceeds from all voluntary paid subscriptions go to support our summer internship program. It enabled us to accept and support a record number of 62 summer interns that joined us in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn't do this expanded program without the funds coming in through Ground Truths. Thank you! Get full access to Ground Truths at erictopol.substack.com/subscribe

The treatment paradigm for non–muscle invasive bladder cancer (NMIBC) has shifted considerably since the FDA established a formal definition of Bacillus Calmette-Guérin (BCG)–unresponsive disease, opening the door to a wave of new intravesical and gene therapies, according to Saum Ghodoussipour, MD.In a conversation with CancerNetwork® on the Oncology On the Go podcast, Ghodoussipour, director of the Bladder and Urothelial Cancer Program at Rutgers Cancer Institute and associate professor of surgery at Robert Wood Johnson Medical School, discussed the distinction between real-world “BCG-exposed” disease and the FDA's stricter, trial-oriented definition of BCG unresponsiveness. The agency's definition accounts for persistent papillary disease, carcinoma in situ, or stage progression within specific timeframes following adequate BCG induction and maintenance.Ghodoussipour walked through how the bladder-sparing armamentarium has expanded since 2020, when pembrolizumab (Keytruda) became the first novel agent approved for BCG-unresponsive disease. He detailed how nadofaragene firadenovec (Adstiladrin), nogapendekin alfa inbakicept-pmln (Anktiva), and TAR-200 (Inlexzo) have since given patients and clinicians a broader menu of options beyond radical cystectomy, each with distinct dosing schedules, response rates, and durability data drawn from single-arm trials.He also addressed how a persistent global BCG shortage is reshaping treatment decisions, noting that some centers, including his own, have adopted third-dose maintenance schedules rather than full-dose, 3-year courses, informed by EORTC data showing no difference in progression or overall survival despite a modest reduction in recurrence prevention. Ghodoussipour further discussed how emerging comparative trials, such as the ECOG-led EA8212/BRIDGE trial (NCT05538663) evaluating BCG against gemcitabine/docetaxel combination therapy, may help resolve open questions around sequencing and allocation.1On the surgical side, Ghodoussipour emphasized that radical cystectomy remains a guideline-recommended option for BCG-unresponsive disease and pointed to data from the CISTO trial (NCT03933826) suggesting that patient-reported quality of life may actually improve after cystectomy compared with prolonged bladder-sparing attempts.2 Still, he noted that improving risk stratification, using biomarkers such as circulating tumor DNA and the AI-driven Vesta Bladder test, may help identify which patients are the best candidates for continued bladder preservation.“[NMIBC] has been booming the last few years,” Ghodoussipour said. “I'm fortunate to have been in such an exciting space because…it's getting better for our patients. But in order for us to reach the point where we can confidently and consistently cure these patients, we really got to get down to tumor biology.”Throughout the conversation, Ghodoussipour underscored the importance of multidisciplinary collaboration among urologists, medical oncologists, and radiation oncologists as systemic therapies and checkpoint inhibitor combinations, including regimens studied in the phase 3 CREST (NCT04165317) and POTOMAC trials (NCT03528694), increasingly enter the BCG-naive and BCG-unresponsive settings.3,4 He also stressed that shared decision-making, better patient-reported outcome data, and continued discovery work into tumor biology will be essential to bring greater consistency to treatment sequencing in the years ahead.References1. Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE). Clinicaltrials.gov. Updated July 17, 2026. Accessed September 9, 2026. https://tinyurl.com/w9axbzks2. Gore JL, Wolff EM, Nash MG, et al. Twelve-month results from the CISTO study comparing radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle-invasive bladder cancer. J Clin Oncol. 2025;44(4):274-285. doi:10.1200/JCO-25-013243. Powles T, Shore N, Galsky M, et al. Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study. J Clin Oncol. 2025;43(suppl 17):4517. doi:10.1200/JCO.2025.43.16_suppl.45174. De Santis M, Redorta J, Nishiyama H, et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. The Lancet. 2025;406(10516):2221-2234. doi:10.1016/S0140-6736(25)01897-5

Nutrition Nugget! Bite-sized bonus episodes offer tips, tricks and approachable science. This week, Jenn is talking about Retatrutide, the third-generation injectable making waves as the most powerful weight-loss drug studied yet. It targets three hormone pathways at once instead of just one or two, and early trial participants have lost staggering amounts of weight, some over 30 percent of their body weight. But is more always better? Jenn breaks down how this triple mechanism works in the body, what the research shows so far, and why it might finally help the roughly 10 percent of people who never responded to earlier GLP-1s. Still, she has been raising the same concerns since Ozempic first came onto the scene, and this new drug is no exception. Is Retatrutide the breakthrough the weight loss world has been waiting for, or just a stronger version of the same unanswered questions? Tune in to hear Jenn's full take. Like what you're hearing? Be sure to check out the full-length episodes of new releases every Wednesday. Have an idea for a nutrition nugget? Submit it here: https://asaladwithasideoffries.com/index.php/contact/ RESOURCES:Become a Happy Healthy Hub MemberJenn's Free Menu PlanA Salad With a Side of FriesA Salad With A Side Of Fries MerchA Salad With a Side of Fries InstagramOzempicAmerican Diabetes Association Retatrutide—A Game Changer in Obesity Pharmacotherapy - PMCGlucagon | HormonesInternational Journal of Molecular SciencesHyperglycemia vs. Hypoglycemia: Differences in Causes and Symptoms - GoodRxGlucagon Control on Food Intake and Energy Balance - PMCLilly Phase 3 StudyComparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials - ScienceDirectLilly - RetatrutideWhat Is Osteoarthritis? Causes, Symptoms, and Treatments - GoodRxPotential Retatrutide Benefits You Should Know About - GoodRxClinical TrialsStudy Details | NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | ClinicalTrials.govClinical TrialsStudy Details | NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)ClinicalTrials.govClinical TrialsNCT07035093 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | ClinicalTrials.gov11 GLP-1 Side Effects You Should Know About - GoodRxTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | New England Journal of Medicine Counterfeit DrugsPeptides for Weight Loss: What They Are and How They Work - GoodRxJenn Trepeck, Nutrition Nugget, Salad With A Side Of Fries, Health Tips, Wellness Tips, Retatrutide, Glp 1, Gip, Glucagon, Weight Loss, Ozempic, Wegovy, Mounjaro, Zepbound, Tirzepatide, Semaglutide, Insulin Sensitivity, Gastric Emptying, Appetite Suppression, Blood Sugar Control, A1c, Glycated Hemoglobin, Liver Steatosis, Fatty Liver Disease, Diabetic Kidney Disease, Type 2 Diabetes, Metabolic Dysfunction, Cardiovascular Risk, Osteoarthritis, Bone Density, Muscle Loss, Body Composition, Clinical Trials, Phase Three Trials, Injectable Medication, Weight Loss Drug, Pharmaceutical Intervention, Hunger Hormone, Satiety, Nausea, Constipation, Gastrointestinal Side Effects, Compounding Pharmacy, Counterfeit Medication, Obesity Treatment, Incretin Hormone, Retatrutide Weight Loss Results, Third Generation Glp 1 Medication

Would you participate in a clinical trial? On the latest episode of BloodStream, Patrick and Amy explore the personal decisions behind research participation. Kevin Finkle joins the I'm Fine segment to share his experience participating in multiple clinical studies and what has shaped his decision to keep getting involved. Later, Benny Sorensen, MD, PhD, CEO of Hemab Therapeutics, offers a look at the role patients play in moving research forward and why asking questions matters. Whether you've participated in research, are considering a study, or have simply wondered, "Are clinical trials for me?" this episode is for you. Show Notes: The Bleeding Edge   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   I'm Fine is presented by @SanofiUS    Subscribe: The BloodStream Podcast   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter  BloodStream on Instagram BloodStream on LinkedIn BloodStream on TikTok  

Clinical trials often collect far more blood than an assay actually needs. Dr. Joleen White asks a more disciplined question: What information is required to make a sound decision, and how little sample can be collected without compromising that decision?In this episode of BioTalk Unzipped, recorded at the 2026 AAPS National Biotechnology Conference in San Diego, Dr. Chad Briscoe sits down with Joleen to explore patient-centric sampling, dried blood microsampling, global bioanalytical capacity, and the values behind better drug development.Joleen traces her path from a childhood friendship with someone living with cystic fibrosis to a career spanning BioMarin, BMS, Biogen, EMD Serono, the Gates Medical Research Institute, and BioData Solutions. She explains why bioanalysis became her way to help patients, why she eventually moved beyond the bench, and how global health work changed the way she thinks about laboratory infrastructure and clinical-trial design.The conversation then turns practical. Joleen defines patient-centric sampling, describes the Mitra dried blood collection device, and discusses a first-in-human RSV monoclonal antibody study in which paired dried-blood and serum samples led to aligned PK conclusions. She and Chad examine regulatory acceptance, remote collection, pediatric sampling, local laboratory capacity in African countries, scientific inclusion, career choices, AI, mass-spectrometry sensitivity, and whether long-standing sample-volume and stability expectations still serve patients.SponsorsTruTechnologies provides live clinical trial execution and oversight through point-of-care data capture. Learn more: https://trutechnologies.ai/Leucentra provides specialized IT consulting and services for life sciences and healthcare. Learn more: https://leucentra.com/In this episode, you will hear• How a personal connection to cystic fibrosis shaped Joleen's patient-first career• Why bioanalysis connects analytical rigor to decisions about drug safety, exposure, and patient benefit• What patient-centric sampling means beyond simply collecting less blood• How dried blood microsampling can support PK, immunogenicity, and viral-neutralization assessments• What Joleen's team learned by comparing dried blood with serum in a first-in-human study• Why smaller samples and remote collection can reduce burdens on patients, caregivers, sites, and enrollment• Why sustainable global health research depends on locally led scientific and laboratory capacity• How legacy automation can slow innovation and create opportunities for newer laboratory networks• Why inclusion and access expand both the scientific workforce and the quality of science• How personal values can guide career decisions more effectively than a rigid five-year plan• Why advances in mass spectrometry should prompt a fresh look at sample volumes and stability expectationsGuest and hostDr. Joleen White is a Senior Bioanalytical Consultant at BioData Solutions with more than 20 years of experience across regulated bioanalysis, ligand-binding assays, immunogenicity, cell-based assays, neutralizing-antibody assays, and data science.Connect with Joleen: https://www.linkedin.com/in/joleenwhite/BioData Solutions: https://www.bdatasolutions.com/Dr. Chad Briscoe is the co-host of BioTalk Unzipped and conducts this onsite conversation from AAPS NBC.Connect with Chad: https://www.linkedin.com/in/chadbriscoe/Resources mentionedOpen-access RSM01 dried blood microsampling study:https://pubmed.ncbi.nlm.nih.gov/39696004/Patient Centric Sampling Interest Group:https://www.pcsig.org/Follow BioTalk UnzippedWebsite and all episodes: https://www.biotalkunzipped.com/YouTube: https://www.youtube.com/@BioTalkUnzippedBioTalk Unzipped unzips, unlocks, and uncovers the real stories behind medical progress.

Description: In this episode of The Lead, host Jenelle Dziano, PhD candidate, is joined by Roopinder Sandu, MD, MPH, FHRS and Louise Segan, MBBS, MPH, PhD to discuss the journal article, Weight Loss in Older Patients With Persistent Atrial Fibrillation, The LOSE-AF Randomized Clinical Trial. Together, they review the findings of the LOSE-AF randomized clinical trial examining weight loss in older patients with persistent atrial fibrillation. Learning Objectives Review the key findings of the LOSE-AF randomized clinical trial examining weight loss in older patients with persistent atrial fibrillation. Discuss the role of weight loss in the management of older patients with persistent atrial fibrillation. Examine the clinical implications of the study findings for patients with persistent atrial fibrillation. Host: Jenelle Dziano, PhD candidate   Guests: Roopinder Sandu, MD, MPH, FHRS and Louise Segan, MBBS, MPH, PhD   Disclosures: J. Dziano No relevant disclosures R. Sandu No relevant disclosures L. Segan No relevant disclosures

P.M. Edition for Sept. 8. OpenAI says it's cracked the Navier-Stokes problem, one of the seven Millennium Prize Problems that are the deepest and most difficult unresolved questions in mathematics. WSJ Science of Success columnist Ben Cohen explains why labs like OpenAI are competing—and spending millions—for such breakthroughs. Plus, a dozen nations are imposing new trade restrictions on Israel over the expansion of settlements in the West Bank. And Smithsonian Secretary Lonnie Bunch III, the first African-American and the first historian to lead the institution, is stepping down after more than a year of tension with President Trump. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Amgen has its worst day in more than two decades. And quantum-computing companies rally after U.S. government picks up minority stakes. Imani Moise hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Jeremy Heffner, MD, FACS is a board-certified trauma surgeon, former Chair of Surgery at Lima Memorial Health System, and cofounder of Surgery Unified, one of the largest physician-led communities in surgery. His perspective carries weight because he has spent decades inside operating rooms, hospital leadership, physician culture, and the growing collision between medicine and corporate healthcare. He grew up in a blue-collar Ohio family of firefighters, railroad workers, police officers, and tradespeople. Medicine represented something rare: a career that combined service, stability, and purpose. He pursued engineering, earned his medical degree, completed trauma surgery fellowship training at the University of Michigan, and entered a profession that taught physicians to sacrifice themselves for patients.Then the rules changed.This conversation traces the gap between the medicine physicians were trained to practice and the healthcare industry that emerged around them. Administrative burden expanded. Insurance companies gained influence over treatment decisions. Prior authorization became routine. Hospital systems consolidated. Physicians retained responsibility for outcomes while losing authority over the conditions required to achieve them.Heffner describes watching colleagues struggle with burnout, moral injury, PTSD, and growing frustration with a system that increasingly inserts business incentives between clinicians and patients. He explains why younger physicians are entering medicine with a level of visibility that previous generations never had. They see the paperwork, the denials, the loss of autonomy, and the personal cost before they ever finish training.The discussion moves beyond physician dissatisfaction and into the broader consequences for patients. When insurers delay care, hospitals absorb costs, clinicians absorb stress, and patients absorb uncertainty. The financial incentives remain intact while trust erodes across every level of the healthcare system.At its core, this episode examines what happens when a profession built around service finds itself operating inside an industry built around extraction. The result affects physicians, nurses, caregivers, and every patient forced to navigate the consequences.RELATED LINKSJeremy Heffner⁠Surgery Unified⁠SurgeOn⁠University of Michigan Department of Surgery⁠KevinMD⁠Suck It Up Buttercup⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In recent years, the U.S. Food and Drug Administration (FDA) has approved new biomarker tools for Alzheimer's disease, including blood tests and tracers for brain scans. How are these tools used in research to help develop new Alzheimer's treatments? Dr. Henrik Zetterberg returns to the podcast to discuss how blood tests, brain scans and other biomarker developments are transforming clinical trials and treatments for Alzheimer's disease and other neurodegenerative conditions ahead of his upcoming Healthy Living with Mild Cognitive Impairment (MCI) event. Guest: Henrik Zetterberg, MD, PhD, professor of neurochemistry, University of Gothenburg, visiting professor, University of Wisconsin−Madison and University College London, Biomarker Core leader, Wisconsin Alzheimer's Disease Research Center Show Notes Register and learn more about the upcoming Healthy Living with MCI event featuring Dr. Zetterberg, happening on September 11, 2026, and future programs on our website. Register and learn more about the upcoming Fall Community Conversation, happening on September 29, 2026, on our website. Listen to our past episodes with Dr. Zetterberg, “Addressing Cochrane's Review on Amyloid-Targeting Treatments for Alzheimer's Disease” and “The Future of Fluid Biomarkers for Alzheimer's Disease and Related Dementias,” on our website. Learn more about LATE, mentioned by Dr. Zetterberg at 24:05, by listening to our episode “LATE, Explained” on our website. Read more about the Alzheimer's disease blood tests recently approved by the U.S. FDA on our website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook, Instagram and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production. Learn about Dr. Chin's book, When Memory Fades: What to Expect at Every Stage, from Early Signs to Full Support for Alzheimer's and Dementia.

Will artificial intelligence make statisticians obsolete—or make our expertise even more valuable? In this episode, I speak with independent statistical consultant Chris Harbron about how AI could reshape the role of statisticians in the pharmaceutical industry. Our conversation builds on Chris's paper, Will the Pharmaceutical Industry Need Statisticians in an AI World? We explore what happens when AI generates protocols, statistical analysis plans, programs, and reports. We also discuss why producing a plausible document differs from making sound decisions about clinical development. Chris and I examine the areas where human statisticians continue to add essential value—from navigating trade-offs and challenging assumptions to building trust and accepting accountability. We also share practical ways statisticians can begin working with AI while protecting quality, scientific rigor, and authenticity.

Sunday, September 6, 2026 — Week 36

A new mRNA vaccine for melanoma is making headlines. Moderna and Merck recently announced results from their clinical trial suggesting that this new vaccine, in combination with the cancer drug Keytruda, reduced recurrence rates in patients. The companies have not yet released full data from the trial. So, how does the vaccine work? And does this mark the beginning of a new era of cancer treatments using mRNA vaccine technology? Ira talks with physician Michael Postow, whose patients were part of the drug trial at Memorial Sloan Kettering Cancer Center. Guest: Dr. Michael Postow is chief of the melanoma service at Memorial Sloan Kettering Cancer Center. Transcript will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In 1971, the National Cancer Act transformed cancer into a national research priority. More than 50 years later, the next frontier is no longer defined solely by scientific discovery, but by how quickly knowledge, lived experience, and patient voices can reshape healthcare itself.The concluding chapter of The Cancer Mavericks: A History of Survivorship explores how the cancer advocacy movement continues to evolve in an era of digital communities, social media, precision medicine, and grassroots activism. Building on the work of pioneers such as Mary Lasker, Rose Kushner, and the generations of survivors who followed, today's advocates are expanding the movement beyond awareness to demand health equity, trusted information, patient-centered research, and meaningful representation in healthcare decision-making.The episode examines how technology has transformed advocacy from local support groups into global communities capable of organizing in real time. Researchers, policymakers, nonprofit leaders, and survivors reflect on the growing influence of digital storytelling, online education, and peer-to-peer networks that connect patients across diagnoses, generations, and geographic boundaries. At the same time, they acknowledge new responsibilities: ensuring accurate medical information, combating misinformation, protecting trust, and keeping patients at the center of innovation.The story also looks ahead to the next generation of advocates. Young leaders are applying lessons learned from decades of cancer activism while drawing inspiration from broader movements for social justice, public health, and community organizing. Their work reflects a simple but enduring truth: meaningful change rarely begins inside institutions. It begins when ordinary people refuse to accept that the system cannot improve.Cancer survivorship has never been a finished story. Every generation inherits the progress achieved by those who came before while confronting challenges uniquely its own. The future of survivorship will be shaped not only by scientific breakthroughs, but by those willing to listen, organize, educate, and ensure that every patient's voice helps define what comes next.RELATED LINKSNational Cancer Institute⁠Cancer Moonshot⁠Centers for Disease Control and Prevention | Division of Cancer Prevention and Control⁠HopeLab⁠Tigerlily Foundation⁠Stupid Cancer⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to A Friend for the Long Haul - A Long Covid Podcast! This is the last season 4 episode. I'll be taking a break for a few weeks. Season 5 is going to be about friendship, sex, and relationships and I've already lined up a lot of coaches and therapists who have long covid so we can tap their brains and get some insights. I'm so excited about it!For our season finale, I brought together two lovely people who are actively changing how medicine and research treat chronic illness: Dr. Wes Ely and Dr. Julia Moore Vogel. Sadly, we did have some technical issues and I don't have any video for Dr. Julia, and only got 15 of the 30 minutes of Dr. Ely's audio. Nevertheless, we persist. Dr. Ely joined me first to talk about whole-person care, what he learned from decades in the ICU, and his work leading the REVERSE-LC trial. Then, Dr Julia and I dive into what it means to be both a scientist leading research at Scripps, specifically studying repurposed tirzepatide in the Long COVID Treatment Trial-Tirzepatide (LoCITT-T) trial, and someone navigating Long COVID in real time. She shared something early in our talk that hit me deeply: as patients with limited energy, we do not have to spend our precious reserves trying to convince the wrong doctor when we could be looking for the right one.We talk about step counts as real data, pacing without shame, the emotional toll of medical appointments, and the quiet joy of being able to crochet and craft again after years of visual and cognitive limits.We also get into what it really means to be a "refined badass" when your body is struggling.Thank you so much for being here with me this season. If this episode brought you comfort or clarity, please share it with a friend who needs to feel seen.Timestamps:00:00 - The "refined badass" shirt reveal & opening02:03 - Introducing Dr. Julia Moore Vogel & Dr. Wes Ely03:33 - Why human stories matter in medicine & Janet Keith's story06:00 - Julia's work on the Lockett trial (repurposed tirzepatide)11:53 - Dr. Ely on what doctors miss about Long COVID & infection-associated illness17:57 - Finding the right doctor vs. convincing the wrong one24:35 - What the tirzepatide trial is trying to answer38:17 - How Julia protects her energy and avoids crashes53:28 - Step counts, pacing, and quiet wins56:21 - Crocheting again after years of limits & closing reflectionsTo support me and my work:I have an Amazon wishlist that's totally unhinged and has items to help me, our neurospicy and disabled home of 6, and the pup.Check out my snarky long covid merch shop. I don't keep this money, I filter it into community care and donations to supportive orgs. Follow me on Instagram, TikTok, or Substack. But the biggest way you can support me listening, sharing, liking, and recommending the podcast. Thank you!

Lindsay Guentzel is Chad's former producer at WCCO. She joins Henry Lake to talk about their friendship history and update us on her ongoing health journey. Lindsay shares how drastically her life changed one day when she received her diagnosis, how amazing her partner John has been as a caregiver and what it's like to participate in clinical trials.

In this episode of The Lead, host Deepak Pasupula, MD, MPH, FHRS, is joined by Zaniar Ghazizadeh, MD, and Pugazhendhi Vijayaraman, MD, FHRS, to discuss the journal article, The Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure (The HeartSync-LBBP Randomized Clinical Trial). Together, they review the long-term outcomes of left bundle-branch pacing compared with biventricular pacing in patients with heart failure and discuss the findings of the HeartSync-LBBP randomized clinical trial. Learning Objectives Review the long-term outcomes of left bundle-branch pacing compared with biventricular pacing in patients with heart failure. Discuss the findings of the HeartSync-LBBP randomized clinical trial. Examine the clinical implications of comparing left bundle-branch pacing with biventricular pacing in heart failure. Host: Deepak Pasupula, MD, MPH, FHRS   Guests: Zaniar Ghazizadeh, MD and Pugazhendhi Vijayaraman, MD, FHRS   Disclosures: D. Pasupula No relevant disclosures   Z. Ghazizadeh No relevant disclosures   P. Vijayaraman Honoraria/Speaking/Consulting Fee: Biotronik, Boston Scientific, Abbott, Medtronic Research: Medtronic Fellowship Support: Medtronic

Check out the full article at: https://oncdata.com/oncology-unfiltered-clinical-trial-enrollment-barriers While clinical trials represent the cutting edge of modern cancer therapy, significant disparities persist in determining who actually enrolls in them. In this episode of Oncology Unfiltered, Melissa Cotrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sat down with Editor in Chief Matthew Hadfield, DO, Medical Oncologist and Assistant Professor of Medicine at Brown University Legorreta Cancer Center, to unpack the practical, structural, and clinical hurdles that prevent eligible patients from accessing potentially lifesaving investigational therapies. Together, they explore how the oncology community can translate trial availability into meaningful access.

This week, we're revisiting a previous conversation with Megan Kamm, Senior Vice President of Client Delivery, and Josh Schroeder, Vice President of Site & Field Operations, to discuss how strong planning, site partnerships, and cross-functional collaboration drive successful trial execution. From feasibility and study startup to patient-centered decision-making, biometrics strategy, and global expansion, they share insights into the operational challenges—and opportunities—behind bringing innovative therapies to patients faster.   01:18 Megan Kamm and Josh Schroeder discuss how their expanded leadership roles have created new opportunities to collaborate across functions and support trial delivery. 03:12 The conversation explores the early decisions that shape trial success, from feasibility planning to selecting the right sites and regions.  04:22 Megan explains how site engagement and thoughtful study design help reduce burden and support successful trial execution. 05:28 Josh and Megan share how project teams, CRAs, and other functions work together to keep studies running smoothly. 06:15 The discussion highlights common challenges during study startup and how proactive planning can reduce delays and enrollment risks. 10:23 Josh and Megan provide examples of how strong collaboration helped accelerate enrollment and deliver data more efficiently. 12:32 Megan discusses how biometrics teams contribute from protocol development through data analysis, helping guide study strategy.  13:32 Josh explains how endpoint priorities and statistical planning influence monitoring strategies throughout a trial. 14:43 The conversation turns to leadership, focusing on training, alignment, and consistent decision-making across global teams. 16:02 Megan and Josh reflect on what sets CTI apart, highlighting a culture centered on patients and collaboration.  18:26 The discussion looks at the future of clinical research, including advances in technology, AI, and trial operations. 20:32 Josh shares insights into CTI's growth in China and the operational considerations that come with expanding into the region.

In 1987, Mary P. Lovato, a member of Kewa Pueblo in New Mexico, was diagnosed with acute leukemia. To receive a bone marrow transplant, she had to travel more than 800 miles from home because specialized cancer care was unavailable through the Indian Health Service. When she returned, she discovered another obstacle: many in her community feared cancer so deeply that they avoided speaking about it altogether.This episode examines how cancer survivorship exposed profound inequities in the American healthcare system. Long before health equity became a national priority, advocates from underserved communities were confronting disparities rooted in geography, poverty, racism, language, underfunded healthcare systems, and historical mistrust of medical institutions. Their work demonstrated that scientific advances alone cannot improve survival if patients cannot reach, afford, or trust the care available to them.The story follows pioneers including Mary P. Lovato, who built the first national Native-led cancer support and education program for Indigenous communities, and Maimah Karmo, founder of the Tigerlily Foundation, whose breast cancer diagnosis inspired a movement to improve early detection, clinical trial participation, and representation for Black women. Their advocacy challenged longstanding barriers to culturally competent care while highlighting persistent inequities in access to screening, fertility preservation, navigation, and innovative treatments.The episode also explores why diversity in clinical research matters. For decades, many cancer clinical trials disproportionately enrolled White patients, limiting both access to promising therapies and the scientific understanding of how treatments perform across different populations. Researchers, patient advocates, and community leaders responded by redesigning outreach, improving patient navigation, reducing logistical barriers, and insisting that affected communities help shape the research itself.Cancer survivorship cannot be measured solely by scientific breakthroughs. It also depends on whether every patient has a meaningful opportunity to benefit from them. The pursuit of health equity remains one of the defining challenges and enduring responsibilities of modern oncology.RELATED LINKSNational Cancer Institute | Cancer Health Disparities⁠Indian Health Service⁠Tigerlily Foundation⁠National Cancer Institute | Cancer Clinical Trials⁠American Indian Cancer Foundation⁠Abramson Cancer Center | University of Pennsylvania⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

There is a startup delay that often goes undetected: source preparation. Ken Getz, executive director at the Tufts Center for the Study of Drug Development, and Rick Ward, chief commercial officer at CRIO, break down what their joint research reveals about protocol-guided source preparation and why it quietly dictates when the first patient can actually enroll. With guest host Deena Bernstein, vice president of business development at Transformative Pharmaceutical Solutions, they walk through the surprising lag sites can face waiting for “final” source materials, why EHR-to-EDC integration is not a universal fix, and the steps sponsors, CROs, and sites can take to reduce startup friction and improve site experience. The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.  

How can we build a patient-reported outcome strategy that captures the patient voice and strengthens clinical development? In this episode of The Effective Statistician Podcast, I speak with Julia Poritz, Senior Research Consultant on Cytel's Evidence, Value, and Access team, about developing and implementing an effective patient-reported outcome (PRO) strategy for clinical trials. We discuss how PROs help us understand the effects of a disease and its treatment from the patient's perspective—including symptoms, physical functioning, health perceptions, and overall quality of life. Julia explains how the Wilson and Cleary model helps us connect these different outcomes and create a clear measurement strategy. We also explore the four essential parts of a PRO strategy: selecting appropriate PRO measures, implementing them within the study, analyzing the data, and reporting the results. Throughout our conversation, we emphasize the importance of early planning, validated measures, patient relevance, regulatory expectations, and comparability with previous clinical trials.

Dr. Heon-Jeong Lee (Korea University, Seoul) joins AJP Audio to discuss an app-based intervention designed to help individuals with mood disorders regulate their circadian rhythms to prevent recurrence of mood episodes.  Afterwards, Dr. Ned Kalin will join us again to discuss the rest of the September issue of the Journal, which takes a close look at clinical treatment. 00:44     Findings 01:42     How the app works 03:05     Differences between the app and traditional lifestyle advice 04:14     Ethics surrounding shame treatment arms 05:43     Broader applicability of the intervention 06:50     Limitations 08:19     Immediate clinical implications 09:33     Further research 10:08     Kalin interview 10:27     Yeom et al. 16:02     Schacht et al. 20:31     Khosravani et al. 24:52     Peterson et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org

In this new episode of Speaking of SurgOnc, Dr. Rick Greene & Dr. Dennis Holmes discuss the article: "Cryoablation: A Minimally Invasive Alternative for Early-Stage Breast Cancer: 6-Year Outcomes of the FROST Clinical Trial" from the April 2026 issue of the Annals of Surgical Oncology.

In his weekly clinical update, Daniel Griffin and Vincent Racaniello are disheartened by the suggested change in federal vaccine recommendations, how Florida rolled back 4 childhood vaccine school requirements, results from a clinical trial suggesting that IPV can be used for outbreak control in IPV only countries, the continued national cyclosporiasis and screwworm outbreaks, size of the Ebola outbreak in the Congo, the death of 2 children in Pennsylvania from measles and the economic cost of the measles outbreak before Dr. Griffin deep dives into the use of monoclonal antibodies and remdesivir to treat Bundibugyo virus infection, measles outbreak, recent statistics RSV, influenza, SARS-CoV-2 infections, access and how pay for Paxlovid, , where to go for answers about long COVID-19, clinical guidelines for treating long COVID, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making (Federal Register) HHS Seeks Public Input on Federal Vaccine Recommendation Categories and Shared Clinical Decision-Making (US Department of Health and Human Services) HPV Vaccination and Risk of Head and Neck Cancers: A Large Real-World Cohort Study (International Society for Infectious Diseases) Monkeypox Virus Surveillance — United States, 2024–2025 (CDC: MMWR) Clinical Trials (ClinicalTrials.gov) Effect of inactivated poliovirus vaccine on nasal mucosal immunity and pharyngeal shedding following novel oral poliovirus vaccine type 2 challenge: A randomized, open-label trial (JID) IPOL package insert (FDA) Florida Prepares to Roll Back School Vaccine Requirements (NOTUS) Florida's Department of Health removes 4 vaccines from required list for public schools (CIDRAP) Surveillance of Cyclosporiasis (CDC: Cyclosporiasis) Infectious Disease Outbreaks (Michigan: Health & Human Services) Cyclosporiasis Cases in North Carolina (North Carolina: Division of Public Health) Cyclospora Infection (Cyclosporiasis) (NYC Health) Missouri Communicable Disease Report (2026) (Missouri Health) TWiP 285: Why is cyclospora hard to contain: Parasitologists explain the 2026 US outbreak (microbeTV:TWiP) Dashboard SCREWWORM.Gov (USDA: Animal and Plant Health Inspection Service) CDC Activates Emergency Operations Center for New World Screwworm Response (CDC Newroom) Ebola virus (AP News) What to know about the outbreak of a rare kind of Ebola (AP News) Congo's Ebola outbreak is on track to surpass the deadliest one in history, WHO chief says (AP News) A look at major Ebola outbreaks and when the disease was first identified (AP News) Mobile gold miners in eastern Congo complicate health workers' efforts to contain Ebola (AP News) How Congo is battling an Ebola outbreak complicated by aid cuts, armed rebels and anger (AP News) Here's data showing Congo's Ebola outbreak is on track to surpass history's largest (AP News) Ebola dashboard (ebola.fyi) EBOLA: The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo (WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) A case of Bundibugyo virus disease treated with monoclonal antibodies and remdesivir (Nature Medicine) Post-Exposure Prophylaxis with a monoclonal antibody cocktail Following Bundibugyo Ebolavirus Exposure in Adults and Children (Nature Medicine) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Measles (VDH: Virginia Department of Health) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) HAP's Latest News Pa. Launches New Measles Dashboard (Hospital + HealthSystem Association of Pennsylvania) Measles (Commonwealth of Pennsylvania) Pennsylvania Department of Health Confirms Two Measles-Associated Deaths (Commonwealth of Pennsylvania) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Do vaccinated cases transmit measles? A systematic review and meta-analysis (Expert Review of Vaccines) County, district and community-level measles transmission in the United States in 2013−2025 (Nat Medicine) Quantifying the cost of measles outbreak in the U.S. and how costs scale with outbreak size (Vaccine) Each measles case in 2025 US outbreak cost almost $60,000, study estimates, or $134 million total (CIDRAP) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Cardiac outcomes following SARS-CoV-2 infection versus BNT162b2 vaccination in adolescents and young adults: a cohort study of 4 million individuals (Vaccine) mRNA COVID vaccine linked to lower risk of myocarditis in teens, youngadults (CIDRAP) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Trump Officials Falsely Connect Covid Vaccines to Miscarriage (NY Times) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1352 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

In 2000, Katie Couric underwent a live colonoscopy on national television following the death of her husband, Jay Monahan, from colorectal cancer at age 42. The broadcast demystified a procedure many Americans feared, led to an estimated 20% increase in colonoscopy screenings, and became one of the clearest examples of how public storytelling can change healthcare behavior.This episode examines how celebrities, journalists, filmmakers, and entertainers helped reshape the public conversation about cancer during a period when survivorship was becoming increasingly visible. As breakthroughs in targeted therapies, immunotherapy, and early detection allowed more people to live beyond cancer, public figures used their platforms to encourage screening, reduce stigma, and accelerate research. Their influence extended far beyond awareness campaigns, helping transform cancer from a private diagnosis into a national public health conversation.Central to this story is Laura Ziskin, the Hollywood producer behind Pretty Woman and the Spider-Man films, whose metastatic breast cancer diagnosis inspired the creation of Stand Up To Cancer. Working alongside Couric and leaders from entertainment, journalism, and biomedical research, Ziskin championed a new funding model that required multidisciplinary scientific collaboration, helping accelerate discoveries that contributed to multiple FDA-approved cancer therapies. The episode also highlights the advocacy of actor Patrick Dempsey, whose family's experience with ovarian cancer led to the creation of the Dempsey Center, expanding support for patients and caregivers beyond medical treatment.The story also asks what celebrity advocacy often leaves unsaid. Financial toxicity, caregiver burden, chronic pain, mental health, and the long-term effects of treatment rarely receive the same attention as dramatic diagnoses or breakthrough cures. As cancer survivorship continues to evolve, the greatest challenge may not be convincing people to care about cancer, but helping them understand what it truly means to live with and beyond it.RELATED LINKSStand Up To Cancer⁠Katie Couric Media⁠Dempsey Center⁠American Association for Cancer Research⁠National Cancer Institute⁠Dana-Farber Cancer Institute | Adult Survivorship Program⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2006, a landmark report titled Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer confirmed what young survivors had been saying for years. While survival rates for children and older adults had steadily improved, adolescents and young adults had experienced decades of stalled progress. They had become cancer's lost generation.This episode explores how young adult survivors transformed their shared isolation into one of the most influential grassroots movements in cancer advocacy. Diagnosed during the years typically devoted to education, careers, relationships, and starting families, patients between the ages of 15 and 39 confronted challenges that extended far beyond treatment. Fertility preservation, sexual health, employment, financial toxicity, insurance, and long-term quality of life were rarely discussed in oncology clinics, leaving many to navigate survivorship alone.The episode follows advocates including Tamika Felder, Lindsay Avner, Heidi Adams, Doug Ulman, and Dr. Archie Bleyer, whose research and advocacy fundamentally changed how medicine understands adolescent and young adult cancer. Through organizations including Planet Cancer, Fertile Hope, the Lance Armstrong Foundation, and later Stupid Cancer, survivors built online communities, educational resources, conferences, and national partnerships that challenged long-standing assumptions about cancer care. Their work helped establish fertility preservation as a standard discussion before treatment, expanded research dedicated to adolescent and young adult oncology, and elevated quality of life as a critical clinical outcome alongside survival.The movement also demonstrated the power of lived experience to reshape medicine. Survivors became researchers, educators, nonprofit founders, and policy advocates, insisting that cancer care account not only for years of life saved, but for the lives patients hoped to build afterward.What began as a search for peers evolved into a national movement that permanently transformed adolescent and young adult oncology. Today, dedicated research programs, clinical fellowships, survivorship resources, and patient advocacy organizations continue to build on the foundation these young cancer mavericks created.RELATED LINKSNational Cancer Institute | Adolescent and Young Adult (AYA) Cancer Program⁠Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer⁠American Society of Clinical Oncology | Fertility Preservation Guidelines⁠Stupid Cancer⁠Livestrong Foundation⁠Journal of Adolescent and Young Adult Oncology⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

P.M. Edition for Aug. 24. Treasury Secretary Scott Bessent says the U.S. will go after countries and companies that do business with Iran. White House economic policy reporter Brian Schwartz says it's unclear what will happen with Iran's top trading partner: China. Plus, President Trump escalates the trade conflict with Canada, threatening 50% tariffs on autos. And Heard on the Street columnist David Wainer discusses the challenges Moderna faces in fulfilling investor hopes for a sweeping new era for cancer treatment. Pierre Bienaimé hosts. The AI Therapist: A WSJ Podcast Series  Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cognitive changes in MS—fluctuations in processing speed, memory, and executive function—can significantly impact daily life, yet they're often misunderstood or overlooked in routine clinical exams. This week, we are joined by Dr. Anna Kratz, clinical psychologist and Professor in the Department of Physical Medicine and Rehabilitation at the University of Michigan, to discuss actionable, evidence-based ways to navigate cognitive challenges.  Dr. Kratz breaks down the latest findings from the CogDetect-MS study, exploring how daily symptom fluctuations, complex medication regimens, and common substances like caffeine and cannabis influence brain fog. She also shares practical compensatory workarounds and introduces a no-cost digital self-management resource, My MSToolKit. We'll also explain the new framework for describing MS that's been proposed by the International Advisory Committee on Clinical Trials in Multiple Sclerosis. We're sharing study results that reveal why detecting even a single silent lesion on an MRI should trigger an immediate conversation about stepping up to high-efficacy therapy. And we'll tell you about 2 advanced MRI markers that can predict future cognitive decline — even in the absence of any relapses or new lesions on MRI. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Maintaining and improving cognitive function  :22 The International Advisory Committee on Clinical Trials in Multiple Sclerosis calls for updating the way MS is described   1:12 A study provides evidence for switching your DMT when there's even a single silent lesion on your MRI   6:53 Scientists identify two MRI markers that can predict future cognitive decline in early relapsing-remitting MS   10:53 Dr. Anna Kratz discusses maintaining and improving cognitive function  15:33  Share this episode  42:13 Next week  42:33 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/469 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com PAPER: Towards a Biologically Informed Description of Multiple Sclerosis Disease Course -- A Roadmap for Transition https://rdcu.be/fxBw1 STUDY: Treatment Escalation After Clinically Silent MRI Lesions in Relapsing-Remitting Multiple Sclerosis https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awag252/8741305 STUDY: Paramagnetic Rim Lesions and Choroid Plexus Volume at Diagnosis Are Associated With Cognitive Progression Independent of Relapse and MRI Activity in Early Relapsing-Remitting Multiple Sclerosis https://onlinelibrary.wiley.com/doi/10.1002/acn3.70448 REGISTER: ECTRIMS Patient Community Day https://ectrimspatientcommunity.eu JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 469 Guest: Dr. Anna Kratz Privacy Policy